No DLTs were observed in the monotherapy(n = 30) or combination (n = 28) therapy. LY3321367 TRAEs occurred in ≥2 patients.In the NSCLC monotherapy expansion cohort, outcomes varied: anti-PD-1/L1 refractory patients [N = 23, ORR 0%, DCR 35%, PFS 1.9 months] versus anti-PD-1/L1 responders(n = 14, ORR 7%, DCR 50%, PFS 7.3 months).In combination expansion cohorts (n = 91),ORR and DCR were 4% and 42% [53]. Here, PDCD1 is linked to non-small cell lung carcinoma.